A Phase II Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab-rwlc (Libtayo) in Subjects With Recurrent or Progressive Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Cemiplimab (Primary) ; INXN 2001 (Primary) ; Veledimex (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors ZIOPHARM Oncology
- 07 Nov 2019 According to a ZIOPHARM Oncology media release, the first first six patients have been dosed in this study and are completing the required monitoring period prior to the resumption of enrollment.
- 01 Jul 2019 Status changed from planning to recruiting.
- 27 Jun 2019 According to a ZIOPHARM Oncology media release, this trial will be conducted at approximately 10 hospitals specializing in the treatment of brain cancers in the United States.